secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001213900-24-066630
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar Q2 net loss $52.4M, cash $290.6M, rezpegaldesleukin Phase 2b on track for H1 2025 topline
--------------------------------------------------------------------------------

- Net loss Q2 2024 $52.4M ($0.25/share) vs $51.1M ($0.27) Q2 2023; non-GAAP net loss $39.1M ($0.19).
- Cash and investments $290.6M at June 30, 2024, down from $329.4M at Dec 31, 2023; runway into Q3 2026.
- Revenue Q2 2024 $23.5M vs $20.5M Q2 2023; R&D expense flat at $29.7M; non-cash restructuring/impairment $13.3M.
- Rezpegaldesleukin Phase 2b enrollment on track; topline data expected H1 2025 (atopic dermatitis) and mid-2025 (alopecia areata).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390024066630/0001213900-24-066630-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390024066630/ea0210855-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-066630

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer